罗马尼亚的艾滋病毒与肾移植:索引案例。

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL
Romanian Journal of Internal Medicine Pub Date : 2024-06-07 Print Date: 2024-09-01 DOI:10.2478/rjim-2024-0020
Bogdan Marian Sorohan, Gener Ismail, Cristiana Oprea, Dorina Tacu, Ileana Constantinescu, Liliana Domnișor, Ionuț Manea, Ioanel Sinescu, Cătălin Baston
{"title":"罗马尼亚的艾滋病毒与肾移植:索引案例。","authors":"Bogdan Marian Sorohan, Gener Ismail, Cristiana Oprea, Dorina Tacu, Ileana Constantinescu, Liliana Domnișor, Ionuț Manea, Ioanel Sinescu, Cătălin Baston","doi":"10.2478/rjim-2024-0020","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Human immunodeficiency virus (HIV) is no longer considered a contraindication for kidney transplantation (KT). KT management in HIV patients is a complex process with challenges, such as drug interactions between immunosuppression and antiretroviral (ARV) therapy. In our country, no KT has been performed thus far in this category of patients.</p><p><strong>Case presentation: </strong>We present the case of a 29-year-old female patient with HIV and end-stage renal disease (ESRD) who performed a KT from a related living donor in March 2022. KT immediate evolution was favorable. No transplant-related complications were reported. HIV viral load remained undetectable and CD4+ T cells were constantly > 500 cell/ μL, during the 18 months of follow-up. The main challenge in our case was the drug interaction between the protease inhibitor-based regimen and tacrolimus. This led to tacrolimus overdose, and, subsequently, change in ARV therapy. ARV switching was performed on a regimen based on integrase inhibitor and nucleoside reverse transcriptase inhibitors. After the ARV change, the therapeutic level of tacrolimus was easily reached and maintained. Kidney graft function remained normal during follow-up, despite tacrolimus overexposure, and no rejection or anti-HLA antibodies were observed. Another challenge was related to the donor's hepatitis C virus status (positive antibodies, negative nucleic acid test). The recipient did not develop seroconversion or detectable viremia at 3-, 6-, 12- and 18-months post-KT.</p><p><strong>Conclusion: </strong>We reported the first case of a successful KT in an ESRD patient with HIV in Romania, in whom the post-transplant evolution was favorable.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":" ","pages":"362-368"},"PeriodicalIF":1.6000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV and kidney transplantation in Romania: The index case.\",\"authors\":\"Bogdan Marian Sorohan, Gener Ismail, Cristiana Oprea, Dorina Tacu, Ileana Constantinescu, Liliana Domnișor, Ionuț Manea, Ioanel Sinescu, Cătălin Baston\",\"doi\":\"10.2478/rjim-2024-0020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Human immunodeficiency virus (HIV) is no longer considered a contraindication for kidney transplantation (KT). KT management in HIV patients is a complex process with challenges, such as drug interactions between immunosuppression and antiretroviral (ARV) therapy. In our country, no KT has been performed thus far in this category of patients.</p><p><strong>Case presentation: </strong>We present the case of a 29-year-old female patient with HIV and end-stage renal disease (ESRD) who performed a KT from a related living donor in March 2022. KT immediate evolution was favorable. No transplant-related complications were reported. HIV viral load remained undetectable and CD4+ T cells were constantly > 500 cell/ μL, during the 18 months of follow-up. The main challenge in our case was the drug interaction between the protease inhibitor-based regimen and tacrolimus. This led to tacrolimus overdose, and, subsequently, change in ARV therapy. ARV switching was performed on a regimen based on integrase inhibitor and nucleoside reverse transcriptase inhibitors. After the ARV change, the therapeutic level of tacrolimus was easily reached and maintained. Kidney graft function remained normal during follow-up, despite tacrolimus overexposure, and no rejection or anti-HLA antibodies were observed. Another challenge was related to the donor's hepatitis C virus status (positive antibodies, negative nucleic acid test). The recipient did not develop seroconversion or detectable viremia at 3-, 6-, 12- and 18-months post-KT.</p><p><strong>Conclusion: </strong>We reported the first case of a successful KT in an ESRD patient with HIV in Romania, in whom the post-transplant evolution was favorable.</p>\",\"PeriodicalId\":21463,\"journal\":{\"name\":\"Romanian Journal of Internal Medicine\",\"volume\":\" \",\"pages\":\"362-368\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Romanian Journal of Internal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/rjim-2024-0020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Journal of Internal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/rjim-2024-0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

导言:人类免疫缺陷病毒(HIV)不再被视为肾移植(KT)的禁忌症。艾滋病病毒感染者的肾移植管理是一个复杂的过程,充满挑战,例如免疫抑制和抗逆转录病毒(ARV)治疗之间的药物相互作用。在我国,迄今为止还没有为这类患者实施过 KT:我们介绍的病例是一名 29 岁的女性艾滋病病毒感染者和终末期肾病(ESRD)患者,她于 2022 年 3 月接受了相关活体供体的 KT。KT 术后情况良好。未报告移植相关并发症。在 18 个月的随访期间,HIV 病毒载量一直检测不到,CD4+ T 细胞一直大于 500 cells/μL。在我们的病例中,主要的挑战在于以蛋白酶抑制剂为基础的治疗方案与他克莫司之间的药物相互作用。这导致他克莫司用药过量,进而改变了抗逆转录病毒疗法。在更换抗逆转录病毒疗法后,采用了以整合酶抑制剂和核苷类逆转录酶抑制剂为基础的治疗方案。更换抗逆转录病毒疗法后,他克莫司很容易达到并维持治疗水平。在随访期间,尽管他克莫司暴露过量,但肾移植功能仍保持正常,也没有观察到排斥反应或抗 HLA 抗体。另一个挑战与供体的丙型肝炎病毒状态有关(抗体阳性,核酸检测阴性)。受体在接受 KT 后 3、6、12 和 18 个月未出现血清转换或可检测到病毒血症:我们报告了罗马尼亚首例成功进行 KT 的艾滋病 ESRD 患者,其移植后的发展情况良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
HIV and kidney transplantation in Romania: The index case.

Introduction: Human immunodeficiency virus (HIV) is no longer considered a contraindication for kidney transplantation (KT). KT management in HIV patients is a complex process with challenges, such as drug interactions between immunosuppression and antiretroviral (ARV) therapy. In our country, no KT has been performed thus far in this category of patients.

Case presentation: We present the case of a 29-year-old female patient with HIV and end-stage renal disease (ESRD) who performed a KT from a related living donor in March 2022. KT immediate evolution was favorable. No transplant-related complications were reported. HIV viral load remained undetectable and CD4+ T cells were constantly > 500 cell/ μL, during the 18 months of follow-up. The main challenge in our case was the drug interaction between the protease inhibitor-based regimen and tacrolimus. This led to tacrolimus overdose, and, subsequently, change in ARV therapy. ARV switching was performed on a regimen based on integrase inhibitor and nucleoside reverse transcriptase inhibitors. After the ARV change, the therapeutic level of tacrolimus was easily reached and maintained. Kidney graft function remained normal during follow-up, despite tacrolimus overexposure, and no rejection or anti-HLA antibodies were observed. Another challenge was related to the donor's hepatitis C virus status (positive antibodies, negative nucleic acid test). The recipient did not develop seroconversion or detectable viremia at 3-, 6-, 12- and 18-months post-KT.

Conclusion: We reported the first case of a successful KT in an ESRD patient with HIV in Romania, in whom the post-transplant evolution was favorable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Romanian Journal of Internal Medicine
Romanian Journal of Internal Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
3.20
自引率
5.30%
发文量
35
审稿时长
15 weeks
期刊介绍: Romanian Journal of Physics is a journal publishing physics contributions on the following themes: •Theoretical Physics & Applied Mathematics •Nuclear Physics •Solid State Physics & Materials Science •Statistical Physics & Quantum Mechanics •Optics •Spectroscopy •Plasma & Lasers •Nuclear & Elementary Particles Physics •Atomic and Molecular Physics •Astrophysics •Atmosphere and Earth Science •Environment Protection
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信